Endocrine

, Volume 55, Issue 2, pp 336–345 | Cite as

Adrenal crises: perspectives and research directions

  • R. Louise Rushworth
  • David J. Torpy
  • Henrik Falhammar
Review

Abstract

Adrenal crises are life-threatening complications of adrenal insufficiency. These events have an estimated incidence of between 5 and 10  adrenal crises/100 patient years and are responsible for some of the increased morbidity and excess mortality experienced by patients with adrenal insufficiency. Treatment involves urgent administration of IV/IM hydrocortisone and IV fluids. Patient education regarding preventive measures, such as increasing the dose of replacement therapy (“stress dosing”) when sick, using parenteral hydrocortisone as necessary and accessing medical assistance promptly, is still considered the best approach to averting the onset of an adrenal crisis at times of physiological stress, most commonly an infection. However, recent evidence has demonstrated that patient education does not prevent many adrenal crisis events and the reasons for this are not fully understood. Furthermore, there is no widely accepted definition of an adrenal crisis. Without a validated adrenal crisis definition it is difficult to interpret variations in the incidence of adrenal crises and determine the effectiveness of preventive measures. This article aims to review the clinical aspects of adrenal crisis events, to explore the epidemiology, and to offer a definition of an adrenal crisis and to offer a perspective on future directions for research into adrenal crisis prevention.

Keywords

Adrenal insufficiency Incidence Risk factors Morbidity Mortality 

Notes

Acknowledgments

HF is supported by the Magnus Bergvall Foundation, Karolinska Institutet, and the Stockholm County Council.

Funding

No funding was received for this review.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    M.M. Erichsen, K. Lovas, K.J. Fougner, J. Svartberg, E.R. Hauge, J. Bollerslev, J.P. Berg, B. Mella, E.S. Husebye, Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur. J. Endocrinol. 160, 233–237 (2009)CrossRefPubMedGoogle Scholar
  2. 2.
    H. Falhammar, L. Frisén, C. Norrby, A.L. Hirschberg, C. Almqvist, A. Nordenskjöld, A. Nordenström, Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 99(12), E2715–E2721 (2014)CrossRefPubMedGoogle Scholar
  3. 3.
    P. Burman, A.F. Mattsson, G. Johannsson, C. Höybye, H. Holmer, P. Dahlqvist, K. Berinder, B.E. Engström, B. Ekman, E.M. Erfurth, J. Svensson, J. Wahlberg, F.A. Karlsson, Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J. Clin. Endocrinol. Metab. 98(4), 1466–1475 (2013)CrossRefPubMedGoogle Scholar
  4. 4.
    R. Bergthorsdottir, M. Leonsson-Zachrisson, A. Oden, G. Johannsson, Premature mortality in patients with Addison’s disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006)CrossRefPubMedGoogle Scholar
  5. 5.
    J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 357(9254), 425–431 (2001)CrossRefPubMedGoogle Scholar
  6. 6.
    S. Bensing, L. Brandt, F. Tabaroj, O. Sjoberg, B. Nilsson, A. Ekbom, P. Blomqvist, O. Kampe, Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin. Endocrinol. (Oxf). 69, 697–704 (2008)CrossRefGoogle Scholar
  7. 7.
    S. Hahner, C. Spinnler, M. Fassnacht, S. Burger-Stritt, K. Lang, D. Milovanovic, F. Beuschlein, H.S. Willenberg, M. Quinkler, B. Allolio, High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J. Clin. Endocrinol. Metab. 100(2), 407–416 (2015)CrossRefPubMedGoogle Scholar
  8. 8.
    S.C. Chapman, S. Llahana, P. Carroll, R. Horne, Glucocorticoid therapy for adrenal insufficiency: nonadherence, concerns and dissatisfaction with information. Clin. Endocrinol. (Oxf). 84(5), 664–671 (2016)CrossRefPubMedGoogle Scholar
  9. 9.
    A. Gargya, E. Chua, J. Hetherington, K. Sommer, M. Cooper, Acute adrenal insufficiency: an aide-memoire of the critical importance of its recognition and prevention. Intern. Med. J. 46(3), 356–359 (2016)CrossRefPubMedGoogle Scholar
  10. 10.
    B. Allolio, Extensive experience in endocrinology: adrenal crisis. Eur. J. Endocrinol. 172, R115–R124 (2015)CrossRefPubMedGoogle Scholar
  11. 11.
    S. Hahner, M. Loeffler, B. Bleicken, C. Drechsler, D. Milovanovic, M. Fassnacht, M. Ventz, M. Quinkler, B. Allolio, Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur. J. Endocrinol. 162(3), 597–602 (2010)CrossRefPubMedGoogle Scholar
  12. 12.
    B. Odenwald, U. Nennstiel-Ratzel, H.G. Dörr, H. Schmidt, M. Wildner, W. Bonfig, Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life. Eur. J. Endocrinol. 174(2), 177–186 (2016)PubMedGoogle Scholar
  13. 13.
    L.C. Smans, E.S. Van der Valk, A.R. Hermus, P.M. Zelissen, Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf). 84(1), 17–22 (2016)CrossRefPubMedGoogle Scholar
  14. 14.
    K. Ritzel, F. Beuschlein, A. Mickisch, A. Osswald, H.J. Schneider, J. Schopohl, M. Reincke, Clinical review: outcome of bilateral adrenalectomy in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 98, 3939–3948 (2013)CrossRefPubMedGoogle Scholar
  15. 15.
    N. Reisch, M. Willige, D. Kohn, H.P. Schwarz, B. Allolio, M. Reincke, M. Quinkler, S. Hahner, F. Beuschlein, Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur. J. Endocrinol. 167(1), 35–42 (2012)CrossRefPubMedGoogle Scholar
  16. 16.
    G. Meyer, K. Badenhoop, R. Linder, Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. Clin. Endocrinol. (Oxf). 85(3), 347–353 (2016)CrossRefPubMedGoogle Scholar
  17. 17.
    L. Papierska, M. Rabijewski, Delay in diagnosis of adrenal insufficiency is a frequent cause of adrenal crisis. Int J Endocrinol 2013, 482370 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    S. Gidlöf, H. Falhammar, A. Thilén, U. von Döbeln, M. Ritzén, A. Wedell, A. Nordenström, One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol. 1(1), 35–42 (2013)CrossRefPubMedGoogle Scholar
  19. 19.
    R.L. Rushworth, D.J. Torpy, A descriptive study of adrenal crises in adults with adrenal insufficiency: increased risk with age and in those with bacterial infections. BMC. Endocr. Disord. 14, 79 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    J.S. Bromberg, E.J. Alfrey, C.F. Barker, K.D. Chavin, D.C. Dafoe, T. Holland, A. Naji, L.J. Perloff, L.A. Zellers, R.A. Grossman, Adrenal suppression and steroid supplementation in renal transplant recipients. J. Transpl. 31, 385–390 (1991)CrossRefGoogle Scholar
  21. 21.
    K. White, W. Arlt, Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur. J. Endocrinol. 162(1), 115–120 (2010)CrossRefPubMedGoogle Scholar
  22. 22.
    World Health Organisation: International statistical classification of diseases and health related problems, 10th Revision (ICD 10). Geneva: WHO (2011)Google Scholar
  23. 23.
    S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 101(2), 364–389 (2016)CrossRefPubMedGoogle Scholar
  24. 24.
    T.H. Puar, N.M. Stikkelbroeck, L.C. Smans, P.M. Zelissen, A.R. Hermus, Adrenal crisis: still a deadly event in the 21(st) century. Am. J. Med. 129(3), 339.e1–e9 (2016)CrossRefGoogle Scholar
  25. 25.
    I.J. Elenkov, R.L. Wilder, G.P. Chrousos, E.S. Vizi, The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52(4), 595–638 (2000)PubMedGoogle Scholar
  26. 26.
    R.C. Andrews, O. Herlihy, D.E. Livingstone, R. Andrew, B.R. Walker, Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J. Clin. Endocrinol. Metab. 87(12), 5587–5593 (2002)CrossRefPubMedGoogle Scholar
  27. 27.
    J.E. Zimmerman, A.A. Kramer, D.S. McNair, F.M. Malila, Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit. Care. Med. 34(5), 1297–1210 (2006)CrossRefPubMedGoogle Scholar
  28. 28.
    D. Naik, K.F. Jebasingh, N. Thomas, Delayed diagnosis of graves’ thyrotoxicoisis presenting as recurrent adrenal crisis in primary adrenal insufficiency. J. Clin. Diagn. Res 10(4), OD20–OD22 (2016)PubMedPubMedCentralGoogle Scholar
  29. 29.
    R.L. Rushworth, D.J. Torpy, Adrenal insufficiency in Australia: is it possible that the use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises? Horm. Metab. Res 47(6), 427–432 (2015)CrossRefPubMedGoogle Scholar
  30. 30.
    A.A. Nofal, I. Bancos, K. Benkhadra, N.M. Ospina, A. Javed, Kapoor E, Muthusamy K, Brito JP, Turcu AF, Wang Z, Prokop L, Erickson DZ, Lteif AN, Natt N, Murad MH. Glucocorticoid replacement regimens in chronic adrenal insufficiency: a systematic review and meta-analysis. Endocr. Pract. (2016) Sep 15 [Epub ahead of print]Google Scholar
  31. 31.
    D.J. Torpy Glucocorticoid replacement in adrenal insufficiency; evaluating the evidence for optimal therapy. Endocr. Pract. (2016) On Line before print. doi: 10.4158/EP161591.CO
  32. 32.
    Y. Reznik, Therapeutic innovations in endocrine diseases—Part 2: modified-release glucocorticoid compounds: what good do they provide to the adrenal insufficient patient? Presse. Med. 45(6 Pt 2), e205–e210 (2016)CrossRefPubMedGoogle Scholar
  33. 33.
    R.L. Rushworth, H. Falhammar, C.F. Munns, A.M. Maguire, D.J. Torpy, Hospitalisation in children with Congenital Adrenal Hyperplasia: the importance of younger age, viral infections and acute hypoadrenalism. Int. J. Endocrinol. (2016). doi: 10.1155/2016/5748264
  34. 34.
    I.J. Elenkov, D.G. Iezzoni, A. Daly, A.G. Harris, G.P. Chrousos, Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation. 12(5), 255–269 (2005)CrossRefPubMedGoogle Scholar
  35. 35.
    S. Yang, L. Zhang, Glucocorticoids and vascular reactivity. Curr. Vasc. Pharmacol. 2(1), 1–12 (2004)CrossRefPubMedGoogle Scholar
  36. 36.
    M. Quinkler, P. Dahlqvist, E.S. Husebye, O.A. Kämpe, European emergency card for adrenal insufficiency can save lives. Eur. J. Intern. Med. 1(1), 75–76 (2015)CrossRefGoogle Scholar
  37. 37.
    S. Hahner, S. Burger-Stritt, B. Allolio, Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur. J. Endocrinol. 169(2), 147–154 (2013)CrossRefPubMedGoogle Scholar
  38. 38.
    R.L. Rushworth, C. Bischoff, D.J. Torpy, Preventing adrenal crises—home administered subcutaneous hydrocortisone is an option. Int. Med. Journal (in press)Google Scholar
  39. 39.
    B. Harbeck, S. Brede, C. Witt, S. Süfke, H. Lehnert, C. Haas, Glucocorticoid replacement therapy in adrenal insufficiency—a challenge to physicians? Endocr. J. 62(5), 463–468 (2015)CrossRefPubMedGoogle Scholar
  40. 40.
    D. Kampmeyer, H. Lehnert, H. Moenig, C.S. Haas, B. Harbeck, A strong need for improving the education of physicians on glucocorticoid replacement treatment in adrenal insufficiency: an interdisciplinary and multicentre evaluation. Eur. J. Intern. Med. S0953-6205(16), 30075–30079 (2016)Google Scholar
  41. 41.
    S. Hahner, N. Hemmelmann, M. Quinkler, F. Beuschlein, C. Spinnler, B. Allolio, Timelines in the management of adrenal crisis—targets, limits and reality. Clin. Endocrinol. (Oxf). 82(4), 497–502 (2015)CrossRefPubMedGoogle Scholar
  42. 42.
    M.A. Nenke, W. Rankin, M.J. Chapman, N.E. Stevens, K.R. Diener, J.D. Hayball, J.G. Lewis, D.J. Torpy, Depletion of high-affinity corticosteroid-binding globulin corresponds to illness severity in sepsis and septic shock; clinical implications. Clin. Endocrinol. (Oxf). 82(6), 801–807 (2015)CrossRefPubMedGoogle Scholar
  43. 43.
    E.J. Meyer, M.A. Nenke, W. Rankin, J.G. Lewis, D.J. Torpy, Corticosteroid-binding globulin: a review of basic and clinical advances. Horm. Metab. Res. 48(06), 359–371 (2016)CrossRefPubMedGoogle Scholar
  44. 44.
    K. Betito, J. Diorio, M.J. Meaney, P. Boksa, Adrenal phenylethanolamine N-methyltransferase induction in relation to glucocorticoid receptor dynamics: evidence that acute exposure to high cortisol levels is sufficient to induce the enzyme. J. Neurochem. 58(5), 1853–1862 (1992)CrossRefPubMedGoogle Scholar
  45. 45.
    H. Falhammar, H. Filipsson Nystrom, A. Wedell, M. Thoren, Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adcrenal hyperplasia due to hydroxylase deficiency. Eur. J. Endocrinol. 164(2), 285–293 (2011)CrossRefPubMedGoogle Scholar
  46. 46.
    E. Charmandari, G. Eisenhofer, S.L. Mehlinger, A. Carlson, R. Wesley, M.F. Keil, G.P. Chrousos, M.I. New, D.P. Merke, Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 87(7), 3031–3037 (2002)CrossRefPubMedGoogle Scholar
  47. 47.
    H. Falhammar, H. Filipsson, G. Holmdahl, P.O. Janson, A. Nordenskjöld, K. Hagenfeldt, M. Thorén, Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92(1), 110–116 (2007)CrossRefPubMedGoogle Scholar
  48. 48.
    H. Falhammar, H. Filipsson, G. Holmdahl, P.O. Janson, A. Nordenskjöld, K. Hagenfeldt, M. Thorén, Increased liver enzymes in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr. J. 56(4), 601–608 (2009)CrossRefPubMedGoogle Scholar
  49. 49.
    K.S. Petersen, R.L. Rushworth, P.M. Clifton, D.J. Torpy, Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison’s disease—favourable response to dietary management: a case report. BMC. Endocr. Disord. 15, 61 (2015). doi: 10.1186/s12902-015-0058-6 CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    G. Meyer, A. Hackemann, J. Reusch, K. Badenhoop, Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison’s disease). Diabetes Technol. Ther. 14(5), 386–388 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency—a worldwide patient survey. BMC. Endocr. Disord. 12, 8 (2012). doi: 10.1186/1472-6823-12-8 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    R.L. Rushworth, D.J. Torpy, Modern hydrocortisone replacement regimens in adrenal insufficiency patients and the risk of adrenal crisis. Horm. Metab. Res. 47(9), 637–642 (2015)CrossRefPubMedGoogle Scholar
  53. 53.
    G. Meyer, K. Neumann, K. Badenhoop, R. Linder, Increasing prevalence of Addison’s disease in German females: health insurance data 2008-2012. Eur. J. Endocrinol. 170, 367–373 (2014)CrossRefPubMedGoogle Scholar
  54. 54.
    R.L. Rushworth, P. Slobodian, D.J. Torpy, Interruptions to supply of high-dose hydrocortisone tablets and the incidence of adrenal crises. Clin. Endocrinol. (Oxf). 83(6), 999–1000 (2015)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.School of Medicine, SydneyThe University of Notre DameSydneyAustralia
  2. 2.Endocrine and Metabolic UnitRoyal Adelaide Hospital and University of AdelaideAdelaideAustralia
  3. 3.Department of Endocrinology, Metabolism and DiabetesKarolinska University HospitalStockholmSweden
  4. 4.Department of Molecular Medicine and SurgeryKarolinska InstitutetStockholmSweden
  5. 5.Menzies School of Health Research and Royal Darwin HospitalDarwinAustralia

Personalised recommendations